Mylan

Breast Cancer Monoclonal Antibodies Global Market Research Report 2021 Featuring Amgen, Mylan, Merck, Novartis, GSK, Daiichi Sankyo, Biocad, Boehringer Ingelheim, BMS, and Array BioPharma - ResearchAndMarkets.com

Retrieved on: 
수요일, 12월 8, 2021
Health, Oncology, Bristol Myers Squibb, Merck, Trastuzumab, Medicine, Research, American Cancer Society, Growth, Hyaluronidase, Mab, Radiation, Novartis, Woman, Prevalence, GlaxoSmithKline, Triple-negative breast cancer, National Institute of Cancer Research and Hospital, Homeopathy, Sutro Biopharma, Vaccine, Breast cancer, Lung, Patient, Organization, SC, Acupuncture, Cancer, Man, National Institute, History, Mylan, Amgen, Neutralizing antibody, COVID-19, Ductal carcinoma, Pharmacy, Treatment, Boehringer Ingelheim, FDA, Hospital, Yoga, Daiichi Sankyo, Breast, Fine chemical, Birth control, Dietary supplement

Major players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.

Key Points: 
  • Major players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.
  • The breast cancer monoclonal antibodies (mAbs) market consists of sales of monoclonal antibodies by entities (organizations, sole traders and partnerships) that produce breast cancer monoclonal antibodies used as therapy for breast cancer either as monotherapy or combination therapy.
  • The companies engaged in the breast cancer monoclonal antibodies market are primarily focused on the research, development, and production of monoclonal antibodies that are used in early-stage and advanced breast cancer, ductal carcinoma in-situ, triple-negative breast cancer, inflammatory breast cancer, and others.
  • Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibodies market.

$266.80 Billion Active Pharmaceutical Ingredients (API) Markets - Global Outlook & Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
목요일, 11월 4, 2021
Health, Pharmaceutical, Molecule, Safety, USD, Industry, Digitalization, Analgesic, Health, Pfizer, Cipla, Novartis, Investment, Sun Pharma, Ageing, Internet, Growth, CAGR, Awareness, Mylan, API, Artificial intelligence, Pain management, Therapy, Population, Teva Active Pharmaceutical Ingredients, Biotechnology, Fine chemical

The "Active Pharmaceutical Ingredients (API) Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Active Pharmaceutical Ingredients (API) Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The active pharmaceutical ingredients market is expected to reach USD 266.80 billion by 2026, growing at a CAGR of 6.22%.
  • The global active pharmaceutical ingredient (API) market is set to have significant growth in the forecasted period.
  • The global active pharmaceutical ingredients industry by pain management API will grow at a CAGR of 5.76% during the forecast period.

Global Actinic Keratosis Drugs Market 2021-2025 - Market is Poised to Grow by $709.82 Million - ResearchAndMarkets.com

Retrieved on: 
목요일, 10월 21, 2021
Health, Pharmaceutical, 3M, Mylan, Sun Pharma, Growth, Prevalence, Industry, CAGR, Retail, Pharmaceutical industry

The actinic keratosis drugs market is poised to grow by $709.82 million during 2021-2025, progressing at a CAGR of about 4%

Key Points: 
  • The actinic keratosis drugs market is poised to grow by $709.82 million during 2021-2025, progressing at a CAGR of about 4%
    The market is driven by the high prevalence of actinic keratosis and the threat of conversion to fatal disease.
  • The report on the actinic keratosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The actinic keratosis drugs market analysis includes the product segment and geographic landscape.
  • Also, the actinic keratosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth.

HER2 Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
목요일, 10월 21, 2021
Health, Pharmaceutical, Woman, Papillary renal cell carcinoma, Squamous cell carcinoma, Breast cancer, Growth, Cancer, Adenocarcinoma, Organization, History, Patient, World Health Organization, World, Novartis, Pfizer, Risk, Boehringer Ingelheim, Mylan, Pressure, Trastuzumab, COVID-19, American Cancer Society, WHO, HER2, Population, Incidence, Fine chemical, Pharmaceutical industry, Birth control

The "HER2 Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HER2 Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The HER2 inhibitors market consists of sales of HER2 inhibitors and related services by entities (organizations, sole traders, and partnerships) that manufacture HER2 inhibitors.
  • Human epidermal growth factor receptor (HER2) inhibitors slow down or stop cell growth thus reducing the risk for cancer growth.
  • Therefore, the high cost of HER2 inhibitors is expected to hinder the growth of the HER2 inhibitors market.

Global Pegfilgrastim Biosimilars Market Research Report 2021 Featuring Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi - ResearchAndMarkets.com

Retrieved on: 
수요일, 10월 20, 2021
Biotechnology, Pharmaceutical, Health, US Foods, Research, Growth, Inflammation, Association, FDA, Biosimilar, Fresenius (company), Food, Government, Generic, Time, Mylan, COVID-19, Awareness, Acquisition, Intas Biopharmaceuticals, Generic drug, Fine chemical

The "Pegfilgrastim Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pegfilgrastim Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi.
  • During the historic period the pegfilgrastim biosimilar market was restrained by the low number of drug approvals by the FDA.
  • The market currently only has 4 drugs approved for treatment, thus restraining the growth of the market.

Zeevo Group’s Advisory Board Gets Another Boost With Appointment of Transformation and Strategy Expert Kimberly Saxton

Retrieved on: 
월요일, 10월 4, 2021
Software, Networks, Professional Services, Data Management, Transportation, Technology, Travel, Air, Transport, Finance, Aerospace, Consulting, Manufacturing, Coos, Risk, Efficiency, Nike, Saxton, Advisory board, Gartner, Mylan, Treasury, Multimedia, Estée Lauder Companies, Compliance, GoDaddy, Intellectual Ventures, Industry, Deloitte, Group, ISTAT, Growth, Boeing Business Jet, AerCap, Technology, View, Information technology, CIOS, EMEA, Organization, Internal audit, CFOS, Financial services, Management

Zeevo Group LLC (Zeevo), a business, finance, and information technology consulting services firm, unveiled at the onset of the ISTAT EMEA conference the appointment of Kimberly Saxton as the newest member of its Advisory Board.

Key Points: 
  • Zeevo Group LLC (Zeevo), a business, finance, and information technology consulting services firm, unveiled at the onset of the ISTAT EMEA conference the appointment of Kimberly Saxton as the newest member of its Advisory Board.
  • Saxton will lead new initiatives assisting clients C-suite executives, including CFOs, CIOs, and COOs, in enhancing strategies and reengineering processes to deliver value to their enterprises.
  • Ive had many opportunities to develop customized approaches to achieving strategies through complex, global initiatives, reengineered business processes, and enhanced internal controls, commented Kimberly Saxton, Zeevo Group Advisory Board member.
  • For such transformation initiatives to be successful, the support of external experts with extensive transformation experience is pivotal.

OptimizeRx Appoints Seasoned Financial and Operational Executive, Edward Stelmakh as Chief Financial Officer and Chief Operations Officer

Retrieved on: 
목요일, 9월 30, 2021
Arts Council of Princeton, Securities Act of 1933, Partnership, American Foundation for Suicide Prevention, University, Solution, Regulation, Sanofi, Secretary of State of New Jersey, Patient, Mylan, Towson University, Arts council, CEO, Accounting, Acquisition, Growth, Leadership, Science, COVID-19, Technology, Johnson & Johnson, MBA, Information technology, CFO, Forward-looking statement, Organization, Securities Exchange Act of 1934, Digital medicine, COO, Data Analytics Acceleration Library, LabCorp, GLOBE, Management

He succeeds Doug Baker within the financial organization, who will continue as executive vice president of finance and accounting.

Key Points: 
  • He succeeds Doug Baker within the financial organization, who will continue as executive vice president of finance and accounting.
  • The addition of operational focus at the Companys executive level ensures that all internal organizations ultimately remain poised for scalability and growth.
  • His background includes leadership positions across a broad spectrum of financial, commercial, partnership/alliance governance, and operational roles.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Roberto Almodóvar Febles Joins Pii as Head of Aseptic Operations

Retrieved on: 
화요일, 8월 31, 2021
Transfer, Risk assessment, University, OLT, Interamerican University of Puerto Rico, GLOBE, Biophysical environment, Knowledge, Efficiency, Chemical engineering, CMO, Baxter International, Valley, Mylan, University of Puerto Rico at Mayagüez, CDMO, Safety, Amgen, Environmental engineering, Lean Six Sigma, Business administration, Asepsis, AstraZeneca, Management, Fine chemical

Hunt Valley, Maryland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Roberto Almodvar Febles becomes Head of Aseptic Operations at Pharmaceutical International, Inc. (Pii) where he will oversee and manage day-to-day aseptic manufacturing and work closely with Sam Chia, the Head of Aseptic Manufacturing Science and Technology (MS&T) and the Operations Leadership Team (OLT) members.

Key Points: 
  • Hunt Valley, Maryland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Roberto Almodvar Febles becomes Head of Aseptic Operations at Pharmaceutical International, Inc. (Pii) where he will oversee and manage day-to-day aseptic manufacturing and work closely with Sam Chia, the Head of Aseptic Manufacturing Science and Technology (MS&T) and the Operations Leadership Team (OLT) members.
  • Roberto is an experienced manufacturing leader with more than 15 years of progressive experience in aseptic manufacturing as an operator, supervisor and manager, says Dr. Kurt Nielsen, Chief Executive Officer of Pii.
  • I am confident Roberto and the other teams will work to successfully deliver on-time, and right first time, for our clients!
  • Piis Hunt Valley, Maryland campus includes 70 manufacturing suites with four integrated aseptic filling lines delivering quality, safety, and efficiency.

Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise

Retrieved on: 
화요일, 8월 31, 2021
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Company, United States Court of Appeals for the Federal Circuit, LLC, Private Securities Litigation Reform Act, Drug development, CNS, Orange Book, EMA, U.S. Securities and Exchange Commission, Eagle, SEC, District, Research, Nasdaq, Food, Patent, Forward-looking statement, Mylan, United States District Court for the Eastern District of Texas, Orange, Failure, District court, Compliance, United States courts of appeals, Phrase, FDA, 1836 U.S. Patent Office fire, COVID-19, Delaware, Security (finance), Medication, Pharmaceutical industry

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No.

Key Points: 
  • Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No.
  • Eagle is submitting the 483 patent for listing in the U.S. Food and Drug Administrations Orange Book for both BENDEKA and BELRAPZO.
  • On July 6, 2020, the District Court for the District of Delaware had held these asserted patents both valid and infringed.
  • We are pleased that this appellate decision, as well as the newly issued patent, continue to strengthen Eagles intellectual property rights for both BENDEKA and BELRAPZO, stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Report 2021-2026: Adalimumab (Humira) is Currently Dominating the $10 Billion Market

Retrieved on: 
금요일, 8월 27, 2021
Company, Growth, Cancer, Adoption, Indication, Conditional sentence, Diabetes, Research, Adalimumab, Ranibizumab, Asthma, Commerce, Pfizer, Mylan, Clinical trial, Arthritis, Patient, Novartis, Trastuzumab, US, Biosimilar, Celltrion, Patent, Generic drug

DUBLIN, Aug. 27, 2021 /PRNewswire/ -- The "Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 27, 2021 /PRNewswire/ -- The "Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • "Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026" report findings, the Europe biosimilar market opportunity is expected to surpass US$ 10.10 Billion by 2026.
  • In addition, the rising geriatric population in the region is also boosting the growth of the European Biosimilar market.
  • "Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026" Report highlights:
    Insight On Biosimilar Clinical Trials By Company, Indication & Phase: > 100 Biosimilars
    Insight On Commercially available Biosimilars in Market: > 25 Biosimilars
    Development of First Biosimilar Omnitrope: Genotropin
    EMA Approved & Marketed Cancer Biosimilars: Dosage & Price Analysis